Research graph
References from Taurocholic acid attenuates hepatic inflammation in MASH and modulates the PPARγ/NF-κB axis. Local targets link to admitted publications; unresolved targets remain external evidence.
PPARγ signaling and metabolism: the good, the bad and the future
10.1038/nm.3159 · 2013 · External reference
Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives
10.1002/hep.28709 · 2017 · External reference
Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease
10.1186/s43066-024-00378-9 · 2024 · External reference
The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis
10.4049/jimmunol.1700183 · 2017 · External reference
Bile acid activated receptors: integrating immune and metabolic regulation in non-alcoholic fatty liver disease
10.1016/j.livres.2021.08.003 · 2021 · External reference
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
10.1016/j.metabol.2015.12.012 · 2016 · External reference
Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione
10.1074/jbc.m109.099333 · 2010 · External reference
The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases
10.1002/hep.29367 · 2018 · External reference
Bile acids: regulation of synthesis
10.1194/jlr.r900010-jlr200 · 2009 · External reference
Bile acid metabolism and signaling
10.1002/j.2040-4603.2013.tb00517.x · 2013 · External reference
Bile acid metabolism in liver pathobiology
10.3727/105221618x15156018385515 · 2018 · External reference
Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy
10.1152/ajpgi.00223.2019 · 2020 · External reference
Evaluation of methionine content in a high-fat and choline-deficient diet on body weight gain and the development of non-alcoholic steatohepatitis in mice
10.1371/journal.pone.0164191 · 2016 · External reference
A current understanding of bile acids in chronic liver disease
10.1016/j.jceh.2021.08.017 · 2022 · External reference
Altered bile acid metabolome in patients with nonalcoholic steatohepatitis
10.1007/s10620-015-3776-8 · 2015 · External reference
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis
10.1124/jpet.105.085597 · 2005 · External reference
Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets
10.1038/s41392-024-01811-6 · 2024 · External reference
Mechanisms of NAFLD development and therapeutic strategies
10.1038/s41591-018-0104-9 · 2018 · External reference
ACT001 alleviates inflammation and pyroptosis through the PPAR-γ/NF-κB signaling pathway in LPS-induced alveolar macrophages
10.1007/s13258-023-01455-w · 2024 · External reference
A researcher's guide to preclinical mouse NASH models
10.1038/s42255-022-00700-y · 2022 · External reference
A methionine-choline-deficient diet induces nonalcoholic steatohepatitis and alters the lipidome, metabolome, and gut microbiome profile in the C57BL/6J mouse
2024 · External reference
Taurocholic acid and glycocholic acid inhibit inflammation and activate farnesoid X receptor expression in LPS-stimulated zebrafish and macrophages
10.3390/molecules28052005 · 2023 · External reference
Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications–a review
10.1186/1475-2891-13-17 · 2014 · External reference
Liver macrophages revisited: the expanding universe of versatile responses in a spatiotemporal context
10.1097/hc9.0000000000000491 · 2024 · External reference
Epigenetic regulation of peroxisome proliferator-activated receptor gamma mediates high-fat diet-induced non-alcoholic fatty liver disease
10.3390/cells10061355 · 2021 · External reference
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
10.1056/nejmoa2309000 · 2024 · External reference
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
10.1016/s2468-1253(23)00272-8 · 2023 · External reference
Changes in bile acid subtypes and long-term successful weight-loss in response to weight-loss diets: the POUNDS lost trial
10.1111/liv.15098 · 2022 · External reference
Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice
10.1016/j.bbrc.2005.08.070 · 2005 · External reference
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
10.1038/s41401-022-00880-z · 2022 · External reference
Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease
10.3390/biom13081264 · 2023 · External reference
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
10.1038/s41575-018-0082-x · 2019 · External reference
Liver macrophages in tissue homeostasis and disease
10.1038/nri.2017.11 · 2017 · External reference
Alterations in circulating bile acids in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
10.3390/biom13091356 · 2023 · External reference
The nuclear factor NF-kappaB pathway in inflammation
10.1101/cshperspect.a001651 · 2009 · External reference
Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050
10.1001/jamanetworkopen.2024.54707 · 2025 · External reference
Taurine attenuates diabetic nephropathy by suppressing the HMGB1/TLR4/MyD88/NF-κB axis in mice
10.1016/j.intimp.2026.116525 · 2026 · External reference
Taurine attenuates LPS-induced pro-inflammatory cytokine production in IPEC-J2 cells by inhibiting the TLR4-MyD88/TRIF signaling pathway
10.1016/j.micpath.2025.107961 · 2025 · External reference
Peroxisome proliferator-activated receptor gamma: a promising therapeutic target for the treatment of chronic pain
10.1016/j.brainres.2024.149366 · 2025 · External reference
Intestinal barrier dysfunction and gut microbiota in non-alcoholic fatty liver disease: assessment, mechanisms, and therapeutic considerations
10.3390/biology13040243 · 2024 · External reference
Mechanisms and disease consequences of nonalcoholic fatty liver disease
10.1016/j.cell.2021.04.015 · 2021 · External reference
Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH
10.1056/nejmoa2304286 · 2023 · External reference
Liver ACOX1 regulates levels of circulating lipids that promote metabolic health through adipose remodeling
10.1038/s41467-024-48471-2 · 2024 · External reference
Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease
2017 · External reference
Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease
10.3390/antiox11010091 · 2021 · External reference
Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease
2015 · External reference
Exosomal PPARγ derived from macrophages suppresses LPS-induced peritonitis by negative regulation of CD14/TLR4 axis
10.1007/s00011-023-01765-5 · 2023 · External reference
Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells
10.1016/j.jhep.2013.06.023 · 2013 · External reference
Advances in understanding lipopolysaccharide-mediated hepatitis: mechanisms and pathological features
10.3390/cimb47020079 · 2025 · External reference
Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-β1/Smad signaling pathway
10.1007/s13105-020-00777-7 · 2021 · External reference
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits
10.1016/j.jhep.2022.06.012 · 2022 · External reference
TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading
10.1016/j.cmet.2011.11.006 · 2011 · External reference
Role of FXR in bile acid and metabolic homeostasis in NASH: pathogenetic concepts and therapeutic opportunities
10.1055/s-0041-1731707 · 2021 · External reference
Cross-talk between PPARγ, NF-κB, and p38 MAPK signaling mediates the ameliorating effects of bergenin against the iron overload-induced hepatotoxicity
10.1016/j.cbi.2022.110207 · 2022 · External reference
GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation
10.1038/sj.bjp.0705973 · 2004 · External reference
Nonalcoholic steatohepatitis: a review
10.1001/jama.2020.2298 · 2020 · External reference
The role of peroxisome proliferator-activated receptors in the regulation of bile acid metabolism
10.1111/bcpt.13971 · 2024 · External reference
A high serum level of taurocholic acid is correlated with the severity and resolution of drug-induced liver injury
10.1016/j.cgh.2020.06.067 · 2021 · External reference
Nonalcoholic fatty liver disease: pathology and pathogenesis
10.1146/annurev-pathol-121808-102132 · 2010 · External reference
Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease
10.1016/j.bbamcr.2014.05.014 · 2014 · External reference
PPAR-γ with its anti-inflammatory and anti-fibrotic action could be an effective therapeutic target in IBD
2018 · External reference
Suppressing cyclooxygenase-2 prevents nonalcoholic and inhibits apoptosis of hepatocytes that are involved in the Akt/p53 signal pathway
10.1016/j.bbrc.2015.12.096 · 2016 · External reference
MDM2 induces pro-inflammatory and glycolytic responses in M1 macrophages by integrating iNOS-nitric oxide and HIF-1α pathways in mice
10.1038/s41467-024-53006-w · 2024 · External reference
Protective effects of taurochenodeoxycholic acid on aflatoxin B1-induced hepatic pyroptosis and gut-liver dysfunction
10.1016/j.ecoenv.2025.119432 · 2025 · External reference
Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
10.3389/fcell.2023.1199519 · 2023 · External reference
The role of nuclear receptors in the pathogenesis and treatment of non-alcoholic fatty liver disease
10.7150/ijbs.87305 · 2024 · External reference
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
10.1002/hep.30251 · 2019 · External reference
Epidemiology of metabolic dysfunction-associated steatotic liver disease
10.3350/cmh.2024.0431 · 2025 · External reference
A glimpse of the connection between PPARγ and macrophage
10.3389/fphar.2023.1254317 · 2023 · External reference
Bile acids in metabolic dysfunction-associated steatotic liver disease
10.4254/wjh.v17.i8.108606 · 2025 · External reference
Myricanol modulates PPARγ/ACSL1/SCD1 metabolic signaling pathway to promote mitochondria biogenesis and fatty acid β-oxidation in high-fat diet-induced obese mice
10.1016/j.jep.2026.121183 · 2026 · External reference
A high hepatic uptake of conjugated bile acids promotes colorectal cancer-associated liver metastasis
10.3390/cells11233810 · 2022 · External reference
